RT Journal Article SR Electronic T1 Colchicine in Behçet Syndrome: A Longterm Survey of Patients in a Controlled Trial JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.130847 DO 10.3899/jrheum.130847 A1 Vedat Hamuryudan A1 Gulen Hatemi A1 Koray Tascilar A1 Sebahattin Yurdakul A1 Cem Mat A1 Yilmaz Ozyazgan A1 Emire Seyahi A1 Serdal Ugurlu A1 Hasan Yazici YR 2014 UL http://www.jrheum.org/content/early/2014/02/12/jrheum.130847.abstract AB Objective To test the hypothesis that colchicine use during early disease decreases immunosuppressive use in Behçet syndrome (BS) in the long term. Methods Patients with BS who participated in a double-blind, placebo-controlled trial of colchicine 16.6 ± 1.1 years ago were evaluated for immunosuppressive use during the posttrial period. Results We could contact 90/116 patients; 28 (31%) received immunosuppressives during the posttrial period, 14 being from the colchicine arm. Posttrial colchicine use and cumulative duration were similar between patients who received immunosuppressives and those who did not. Conclusion Continuous use of colchicine, even when initiated at an early disease stage, does not seem to decrease the use of immunosuppressives in the long term.